(0.15%) 5 139.00 points
(0.10%) 38 481 points
(0.23%) 17 886 points
(-0.36%) $83.55
(1.72%) $1.956
(0.28%) $2 353.80
(0.54%) $27.69
(1.61%) $936.95
(-0.14%) $0.933
(-0.28%) $10.99
(-0.29%) $0.798
(1.18%) $92.96
0.00% $ 0.0520
Live Chart Being Loaded With Signals
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...
Stats | |
---|---|
Volumen de hoy | 762 848 |
Volumen promedio | 1.17M |
Capitalización de mercado | 41.88M |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $7.15 ( 1993-10-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.20 |
ATR14 | $0.00100 (1.89%) |
Prescient Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Prescient Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $2.43M |
Beneficio Bruto: | $2.43M (99.91 %) |
EPS: | $-0.00960 |
FY | 2023 |
Ingresos: | $2.43M |
Beneficio Bruto: | $2.43M (99.91 %) |
EPS: | $-0.00960 |
FY | 2022 |
Ingresos: | $1.89M |
Beneficio Bruto: | $1.89M (99.93 %) |
EPS: | $-0.00790 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.00680 |
Financial Reports:
No articles found.
Prescient Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $5.72 | 1990-10-25 |
Last Dividend | $7.15 | 1993-10-21 |
Next Dividend | $0 | N/A |
Payout Date | 1993-12-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $12.87 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.22 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
MYS.AX | Ex Dividend Junior | 2023-08-23 | Annually | 0 | 0.00% | |
WGB.AX | Ex Dividend Junior | 2023-10-12 | Semi-Annually | 0 | 0.00% | |
ENN.AX | No Dividend Player | 2023-06-29 | Annually | 0 | 0.00% | |
PE1.AX | Ex Dividend Junior | 2023-07-03 | Semi-Annually | 0 | 0.00% | |
AMH.AX | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
GWA.AX | Ex Dividend Knight | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
RHI.AX | No Dividend Player | 2023-07-10 | Annually | 0 | 0.00% | |
BSE.AX | Ex Dividend Junior | 2023-09-08 | Semi-Annually | 0 | 0.00% | |
LBL.AX | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
STO.AX | Ex Dividend Knight | 2023-08-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.49 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.313 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.318 | 1.500 | -4.65 | -6.97 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 10.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.96 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.08 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00635 | [0 - 30] |
freeCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00476 | -0.00952 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.71 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.126 | 0.800 | -2.50 | -1.996 | [0.5 - 2] |
Total Score | -0.920 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.51 | 1.000 | -0.658 | 0 | [1 - 100] |
returnOnEquityTTM | -0.318 | 2.50 | -2.99 | -6.97 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00952 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.00952 | 2.00 | -0.00317 | -0.00635 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.911 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.46 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.81 |
Prescient Therapeutics
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico